Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Alkermes plc (ALKS)

23.97   -0.23 (-0.95%) 11-28 16:00
Open: 24.22 Pre. Close: 24.2
High: 24.385 Low: 23.82
Volume: 1,198,339 Market Cap: 3,939(M)

Technical analysis

as of: 2022-11-28 4:37:49 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 29.62     One year: 34.59
Support: Support1: 23.32    Support2: 22.05
Resistance: Resistance1: 25.36    Resistance2: 29.62
Pivot: 23.5
Moving Average: MA(5): 24.13     MA(20): 23.53
MA(100): 24.62     MA(250): 25.72
MACD: MACD(12,26): 0.2     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 71.4     %D(3): 69.3
RSI: RSI(14): 55.1
52-week: High: 32.79  Low: 21.75
Average Vol(K): 3-Month: 1,714 (K)  10-Days: 1,538 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ALKS ] has closed below upper band by 32.3%. Bollinger Bands are 8.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 24.44 - 24.58 24.58 - 24.69
Low: 23.47 - 23.66 23.66 - 23.81
Close: 23.72 - 24 24 - 24.21

Company Description

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Headline News

Wed, 23 Nov 2022
How Alkermes (ALKS) Stock Stands Out in a Strong Industry - Nasdaq

Mon, 21 Nov 2022
Peek Under The Hood: RXL Has 10% Upside - Nasdaq

Fri, 18 Nov 2022
IBRX, ALKS and QSI are among after hour movers - STL.News

Thu, 10 Nov 2022
Alkermes's Return On Capital Employed Insights - Alkermes (NASDAQ:ALKS) - Benzinga

Wed, 09 Nov 2022
Alkermes (NASDAQ:ALKS) Releases FY 2022 Earnings Guidance - MarketBeat

Tue, 08 Nov 2022
Alkermes to Participate in the Stifel Healthcare Conference - Alkermes (NASDAQ:ALKS) - Benzinga

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 164 (M)
Shares Float 148 (M)
% Held by Insiders 1.6 (%)
% Held by Institutions 99.4 (%)
Shares Short 8,870 (K)
Shares Short P.Month 9,160 (K)

Stock Financials

EPS -0.38
EPS Est Next Qtl -0.01
EPS Est This Year -0.04
EPS Est Next Year 0.44
Book Value (p.s.) 6.34
Profit Margin (%) -11.5
Operating Margin (%) -10.6
Return on Assets (ttm) -3.8
Return on Equity (ttm) -12.1
Qtrly Rev. Growth -14.2
Gross Profit (p.s.) 5.94
Sales Per Share 6.87
EBITDA (p.s.) -0.25
Qtrly Earnings Growth 0
Operating Cash Flow 51 (M)
Levered Free Cash Flow 83 (M)

Stock Valuations

PE Ratio -63.08
PEG Ratio 3.9
Price to Book value 3.77
Price to Sales 3.48
Price to Cash Flow 77.19

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.